Due to a production error, there was a mistake in Figure 6 as published. The part labels in the figure were not placed correctly. The corrected Figure 6 appears below. The publisher apologizes for this mistake.
Figure 6
The original version of this article has been updated.
Summary
Keywords
acute lymphoblastic leukemia, liquid biopsy, disease monitoring, precision medicine, whole-genome sequencing, structural variation, technical feasibility, diagnostic performance
Citation
Frontiers Production Office (2023) Erratum: Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia: A proof of concept study. Front. Oncol. 12:1124071. doi: 10.3389/fonc.2022.1124071
Received
14 December 2022
Accepted
14 December 2022
Published
04 January 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2022
Updates
Copyright
© 2023 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Pediatric Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.